, Columnist
Allergan's Biosimilar Pullback Won't Be the Last
The market just can't support the crowd of current entrants.
This article is for subscribers only.
The hot new thing in pharma -- "biosimilar" drugs -- is getting so crowded that soon nobody will want to go there any more.
Biosimilars are a relatively new wave of generic-like drugs that substitute for biologic drugs, which are made with living cells rather than chemicals. Many big pharma companies have jumped into the market with both feet.